Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
-- THE-630 demonstrates encouraging safety profile through Cohort 6 , supportive of continued dose escalation -- -- Dose-dependent reductions observed in ctDNA KIT-mutant allele fractions for both... | May 25, 2023
Source: marketscreener.com